Vedanta Biosciences closes extended $45.5 million Series C financing
CAMBRIDGE: Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, has raised an additional $18.5 million as…